Increasing Incidence of Epstein-Barr Virus-related Nasopharyngeal Carcinoma in the United States
Overview
Authors
Affiliations
Background: The incidence of nasopharyngeal carcinoma (NPC) has been historically low in the United States. Although etiological factors differ by histological subtype, Epstein-Barr virus is accepted as the primary risk factor for nonkeratinizing NPC. In light of the changing epidemiology of viral-associated cancers, it is important to evaluate the temporal incidence of NPC in the United States.
Methods: Incidence and survival data from 1973 through 2015 were obtained from the Surveillance, Epidemiology, and End Results program. Stratified analyses were conducted to assess temporal trends in NPC by histological subtype, sex, and race. The data were analyzed using SAS and Joinpoint Regression Software to determine age-adjusted incidence rates, determine trends in the annual percent change, and calculate 5-year relative survival estimates and Kaplan-Meier curves.
Results: Although overall NPC incidence is decreasing in the United States, the nonkeratinizing differentiated subtype is starkly increasing, with an annual percent change of approximately 4% among white males (95% CI, 2.5%-5.2%), white females (95% CI, 1.9%-6.2%), and black males (95% CI, 2.0%, 5.7%); 2.7% among black females (95% CI, 0.8%, 4.6%); and 1.8% among women in the "other" race category (95% CI, 0.4%-3.3%). Racial disparities were noted, with 32% of nonkeratinizing NPC cases among blacks occurring before the age of 40 years. In addition, black males displayed consistently worse survival across all histological subtypes, whereas individuals in the "other" race category, particularly females, experienced the highest 5-year relative survival estimates.
Conclusions: The current results indicate that the Epstein-Barr virus-related, differentiated NPC subtype is increasing across all sexes and races in the United States, with distinct incidence and survival disparities among blacks.
A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma.
Spreafico A, Winquist E, Ho C, OSullivan B, Bouganim N, Chua N Curr Oncol. 2025; 32(1).
PMID: 39851964 PMC: 11763457. DOI: 10.3390/curroncol32010048.
Guo L, Dai Y, Yu Y, Wu S Clin Epidemiol. 2024; 16:769-782.
PMID: 39539417 PMC: 11559420. DOI: 10.2147/CLEP.S490023.
Nasopharyngeal carcinoma survival by histology in endemic and non-endemic areas.
Guo L, Hong J, Wang R, Chen G, Wu S Ann Med. 2024; 56(1):2425066.
PMID: 39529559 PMC: 11559018. DOI: 10.1080/07853890.2024.2425066.
Resveratrol Inhibits Nasopharyngeal Carcinoma (NPC) by Targeting the MAPK Signaling Pathway.
Yi Y, Zhou B, Man T, Xu Z, Tang H, Li J Anticancer Agents Med Chem. 2024; 24(16):1207-1219.
PMID: 38988166 DOI: 10.2174/0118715206319761240705115109.
Pandit S, Sapkota S, Adhikari A, Karki P, Yadav D, Shrestha R PLoS One. 2024; 19(5):e0304371.
PMID: 38820402 PMC: 11142571. DOI: 10.1371/journal.pone.0304371.